BioMarin signs deal worth $475 M with Korea's GC Biopharma and Hanmi Pharm for potential treatment of Fabry Disease ...

BioMarin is paying $70 million upfront to license a Fabry disease drug candidate, expanding the franchise it acquired through ...

US biotech BioMarin Pharmaceutical today announced it has entered into an exclusive worldwide license agreement with GC ...

Agreement grants BioMarin worldwide rights (excluding Korea) to HM15421/GC1134A, a long-acting, subcutaneous, clinical-stage enzyme replacement therapy for Fabry disease. BioMarin ...

Alexander Hardy, BioMarin president and CEO, joins 'Squawk Box' to discuss the FDA's Rare Disease Framework Initiative, the ...

BioMarin licenses long-acting Fabry enzyme replacement therapy HM15421/GC1134A, while Ferring agrees to acquire fertility ...

Hanmi Pharm stock is in focus after BioMarin agreed to license a Fabry disease therapy candidate. Hanmi retains Korean ...

Under the agreement, BioMarin will pay $70 million upfront. GC Biopharma and Hanmi Pharm are jointly eligible to receive up to an additional $405 million in development and commercial milestone ...

Alexander Hardy, BioMarin president and CEO, talks to CNBC "Squawk Box" about the company's M&A strategy and how it's ...

BioMarin Pharmaceutical Inc. announced it has entered into an exclusive worldwide license agreement with GC Biopharma Corp. and Hanmi Pharm Co., Ltd. to develop and commercialize HM15421/GC1134A, an ...

BioMarin Pharmaceuticals said in a statement provided Wednesday that the decision to make layoffs came as part of a push to consolidate its footprint in Novato.

BioMarin Pharmaceutical (BMRN) just put fresh clinical data in front of investors, highlighting five year outcomes for ...